New inhaler drug shows promise for COPD inflammation

NCT ID NCT05270525

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a nebulized drug called ensifentrine can reduce inflammation in the lungs of people with COPD. About 56 adults aged 40-80 who smoke or have smoked will receive both the drug and a placebo at different times over 24 weeks. The main goal is to see changes in sputum cell counts, which indicate inflammation.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COPD are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease COPD, severe early onset

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of Alabama at Birmingham

    RECRUITING

    Birmingham, Alabama, 35205, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • University of Michigan

    RECRUITING

    Ann Arbor, Michigan, 48109, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • University of Pittsburgh Medical Center

    RECRUITING

    Pittsburgh, Pennsylvania, 15213, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••